EV/Sales Ratio: 1.91x
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 1.91x is 13% below its 3-year average of 2.20x, near the low end of its 3-year range (1.70x–2.60x).
As of Monday, June 29, 2026. 6.77% below its 12-month average of 2.05x.
GEHC EV/Sales Ratio Chart
GEHC Average EV/Sales Ratio Chart
GEHC Current vs Average EV/Sales Ratio Chart
GEHC EV/Sales Ratio Metrics
EV/SALES RATIO
1.91x
EV/SALES RATIO AVG TTM
2.05x
EV/SALES RATIO AVG 3Y
2.18x
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-6.77%
CURRENT VS 3Y AVG
-12.35%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GEHC Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $29.59B | 1.91x | 2.05x | 2.18x | N/A |
| ResMed Inc. (RMD)vs › | $28.78B | 5.12x | 6.81x | 6.81x | 8.13x |
| Veeva Systems Inc. (VEEV)vs › | $28.62B | 8.27x | 12.10x | 13.22x | 15.46x |
| Zoetis Inc. (ZTS)vs › | $30.70B | 4.02x | 6.52x | 8.68x | 9.81x |
| Moderna, Inc. (MRNA)vs › | $27.66B | 12.10x | 6.30x | 5.13x | 6.59x |
| Centene Corp. (CNC)vs › | $31.87B | 0.14x | 0.11x | 0.20x | 0.28x |
| Biogen Inc. (BIIB)vs › | $31.98B | 3.58x | 2.84x | 3.28x | 3.56x |
| DexCom, Inc. (DXCM)vs › | $27.00B | 5.77x | 6.51x | 10.03x | 13.72x |
| IQVIA Holdings Inc. (IQV)vs › | $32.26B | 2.82x | 2.92x | 3.23x | 3.53x |
| Medline Inc. (MDLN)vs › | $33.49B | 1.48x | 1.58x | 1.58x | 1.58x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/Sales Ratio FAQ
- What is the EV/Sales ratio for GE HealthCare Technologies Inc. (GEHC)?
- The EV/Sales ratio for GEHC stock is 1.91x.
- Is GE HealthCare Technologies Inc.'s EV/Sales ratio high or low?
- The EV/Sales ratio of 1.91x is 13% below its 3-year average of 2.20x, near the low end of its 3-year range (1.70x–2.60x).
- What is the TTM average EV/Sales ratio for GE HealthCare Technologies Inc. (GEHC)?
- The TTM average EV/Sales ratio for GEHC stock is 2.05x.
- What is the 3Y average EV/Sales ratio for GE HealthCare Technologies Inc. (GEHC)?
- The 3Y average EV/Sales ratio for GEHC stock is 2.18x.
GEHC EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-29 | 1.91x |
| 2026-06-26 | 1.92x |
| 2026-06-25 | 1.90x |
| 2026-06-24 | 1.90x |
| 2026-06-23 | 1.87x |
| 2026-06-22 | 1.80x |
| 2026-06-18 | 1.83x |
| 2026-06-17 | 1.82x |
| 2026-06-16 | 1.86x |
| 2026-06-15 | 1.90x |
| 2026-06-12 | 1.91x |
| 2026-06-11 | 1.89x |
| 2026-06-10 | 1.88x |
| 2026-06-09 | 1.93x |
| 2026-06-08 | 1.90x |
| 2026-06-05 | 1.90x |
| 2026-06-04 | 1.88x |
| 2026-06-03 | 1.84x |
| 2026-06-02 | 1.84x |
| 2026-06-01 | 1.85x |
| 2026-05-29 | 1.84x |
| 2026-05-28 | 1.86x |
| 2026-05-27 | 1.88x |
| 2026-05-26 | 1.89x |
| 2026-05-22 | 1.89x |
| 2026-05-21 | 1.89x |
| 2026-05-20 | 1.89x |
| 2026-05-19 | 1.83x |
| 2026-05-18 | 1.82x |
| 2026-05-15 | 1.81x |
| 2026-05-14 | 1.85x |
| 2026-05-13 | 1.83x |
| 2026-05-12 | 1.84x |
| 2026-05-11 | 1.83x |
| 2026-05-08 | 1.87x |
| 2026-05-07 | 1.82x |
| 2026-05-06 | 1.83x |
| 2026-05-05 | 1.81x |
| 2026-05-04 | 1.81x |
| 2026-05-01 | 1.81x |
| 2026-04-30 | 1.81x |
| 2026-04-29 | 1.78x |
| 2026-04-28 | 1.89x |
| 2026-04-27 | 1.94x |
| 2026-04-24 | 1.90x |
| 2026-04-23 | 1.92x |
| 2026-04-22 | 1.96x |
| 2026-04-21 | 1.98x |
| 2026-04-20 | 2.02x |
| 2026-04-17 | 2.03x |
| 2026-04-16 | 2.00x |
| 2026-04-15 | 2.01x |
| 2026-04-14 | 2.03x |
| 2026-04-13 | 2.01x |
| 2026-04-10 | 2.00x |
| 2026-04-09 | 1.99x |
| 2026-04-08 | 2.01x |
| 2026-04-07 | 1.92x |
| 2026-04-06 | 1.93x |
| 2026-04-02 | 1.93x |
| 2026-04-01 | 1.97x |
| 2026-03-31 | 1.95x |
| 2026-03-30 | 1.90x |
| 2026-03-27 | 1.91x |
| 2026-03-26 | 1.96x |
| 2026-03-25 | 1.98x |
| 2026-03-24 | 1.95x |
| 2026-03-23 | 1.96x |
| 2026-03-20 | 1.92x |
| 2026-03-19 | 1.93x |
| 2026-03-18 | 1.93x |
| 2026-03-17 | 1.98x |
| 2026-03-16 | 1.97x |
| 2026-03-13 | 1.94x |
| 2026-03-12 | 1.93x |
| 2026-03-11 | 1.99x |
| 2026-03-10 | 1.99x |
| 2026-03-09 | 2.06x |
| 2026-03-06 | 2.02x |
| 2026-03-05 | 2.09x |
| 2026-03-04 | 2.14x |
| 2026-03-03 | 2.11x |
| 2026-03-02 | 2.16x |
| 2026-02-27 | 2.26x |
| 2026-02-26 | 2.25x |
| 2026-02-25 | 2.25x |
| 2026-02-24 | 2.25x |
| 2026-02-23 | 2.25x |
| 2026-02-20 | 2.26x |
| 2026-02-19 | 2.23x |
| 2026-02-18 | 2.23x |
| 2026-02-17 | 2.20x |
| 2026-02-13 | 2.17x |
| 2026-02-12 | 2.13x |
| 2026-02-11 | 2.14x |
| 2026-02-10 | 2.14x |
| 2026-02-09 | 2.14x |
| 2026-02-06 | 2.17x |
| 2026-02-05 | 2.21x |
| 2026-02-04 | 2.22x |
| 2026-02-03 | 2.11x |
| 2026-02-02 | 2.14x |
| 2026-01-30 | 2.12x |
| 2026-01-29 | 2.11x |
| 2026-01-28 | 2.12x |
| 2026-01-27 | 2.15x |
| 2026-01-26 | 2.14x |
| 2026-01-23 | 2.13x |
| 2026-01-22 | 2.18x |
| 2026-01-21 | 2.16x |
| 2026-01-20 | 2.11x |
| 2026-01-16 | 2.18x |
| 2026-01-15 | 2.20x |
| 2026-01-14 | 2.26x |
| 2026-01-13 | 2.25x |
| 2026-01-12 | 2.29x |
| 2026-01-09 | 2.30x |
| 2026-01-08 | 2.32x |
| 2026-01-07 | 2.27x |
| 2026-01-06 | 2.29x |
| 2026-01-05 | 2.25x |
| 2026-01-02 | 2.20x |
| 2025-12-31 | 2.18x |
| 2025-12-30 | 2.21x |
| 2025-12-29 | 2.21x |
| 2025-12-26 | 2.22x |
| 2025-12-24 | 2.22x |
| 2025-12-23 | 2.21x |
| 2025-12-22 | 2.23x |
| 2025-12-19 | 2.20x |
| 2025-12-18 | 2.20x |
| 2025-12-17 | 2.19x |
| 2025-12-16 | 2.19x |
| 2025-12-15 | 2.24x |
| 2025-12-12 | 2.23x |
| 2025-12-11 | 2.28x |
| 2025-12-10 | 2.24x |
| 2025-12-09 | 2.21x |
| 2025-12-08 | 2.21x |
| 2025-12-05 | 2.26x |
| 2025-12-04 | 2.20x |
| 2025-12-03 | 2.22x |
| 2025-12-02 | 2.14x |
| 2025-12-01 | 2.12x |
| 2025-11-28 | 2.14x |
| 2025-11-26 | 2.15x |
| 2025-11-25 | 2.14x |
| 2025-11-24 | 2.10x |
| 2025-11-21 | 2.06x |
| 2025-11-20 | 2.02x |
| 2025-11-19 | 1.97x |
| 2025-11-18 | 1.94x |
| 2025-11-17 | 1.93x |
| 2025-11-14 | 1.98x |
| 2025-11-13 | 2.00x |
| 2025-11-12 | 2.03x |
| 2025-11-11 | 1.99x |
| 2025-11-10 | 1.99x |
| 2025-11-07 | 1.98x |
| 2025-11-06 | 2.01x |
| 2025-11-05 | 2.04x |
| 2025-11-04 | 2.01x |
| 2025-11-03 | 2.01x |
| 2025-10-31 | 2.02x |
| 2025-10-30 | 2.03x |
| 2025-10-29 | 2.08x |
| 2025-10-28 | 2.18x |
| 2025-10-27 | 2.15x |
| 2025-10-24 | 2.15x |
| 2025-10-23 | 2.13x |
| 2025-10-22 | 2.10x |
| 2025-10-21 | 2.10x |
| 2025-10-20 | 2.09x |
| 2025-10-17 | 2.05x |
| 2025-10-16 | 2.04x |
| 2025-10-15 | 2.03x |
| 2025-10-14 | 2.01x |
| 2025-10-13 | 2.00x |
| 2025-10-10 | 1.98x |
| 2025-10-09 | 2.06x |
| 2025-10-08 | 2.08x |
| 2025-10-07 | 2.06x |
| 2025-10-06 | 2.11x |
| 2025-10-03 | 2.11x |
| 2025-10-02 | 2.12x |
| 2025-10-01 | 2.09x |
| 2025-09-30 | 2.08x |
| 2025-09-29 | 2.03x |
| 2025-09-26 | 2.02x |
| 2025-09-25 | 1.99x |
| 2025-09-24 | 2.05x |
| 2025-09-23 | 2.07x |
| 2025-09-22 | 2.07x |
| 2025-09-19 | 2.07x |
| 2025-09-18 | 2.05x |
| 2025-09-17 | 2.11x |
| 2025-09-16 | 2.13x |
| 2025-09-15 | 2.14x |
| 2025-09-12 | 2.11x |
| 2025-09-11 | 2.14x |
| 2025-09-10 | 2.10x |
| 2025-09-09 | 2.16x |
| 2025-09-08 | 2.15x |
| 2025-09-05 | 2.09x |
| 2025-09-04 | 2.05x |
| 2025-09-03 | 2.02x |
| 2025-09-02 | 2.00x |
| 2025-08-29 | 2.05x |
| 2025-08-28 | 2.05x |
| 2025-08-27 | 2.06x |
| 2025-08-26 | 2.05x |
| 2025-08-25 | 2.07x |
| 2025-08-22 | 2.08x |
| 2025-08-21 | 2.03x |
| 2025-08-20 | 2.05x |
| 2025-08-19 | 2.05x |
| 2025-08-18 | 2.03x |
| 2025-08-15 | 2.04x |
| 2025-08-14 | 2.04x |
| 2025-08-13 | 2.08x |
| 2025-08-12 | 2.06x |
| 2025-08-11 | 2.03x |
| 2025-08-08 | 2.01x |
| 2025-08-07 | 1.99x |
| 2025-08-06 | 1.96x |
| 2025-08-05 | 1.98x |
| 2025-08-04 | 1.98x |
| 2025-08-01 | 1.96x |
| 2025-07-31 | 1.99x |
| 2025-07-30 | 2.00x |
| 2025-07-29 | 2.14x |
| 2025-07-28 | 2.14x |
| 2025-07-25 | 2.14x |
| 2025-07-24 | 2.12x |
| 2025-07-23 | 2.13x |
| 2025-07-22 | 2.11x |
| 2025-07-21 | 2.06x |
| 2025-07-18 | 2.10x |
| 2025-07-17 | 2.11x |
| 2025-07-16 | 2.09x |
| 2025-07-15 | 2.06x |
| 2025-07-14 | 2.07x |
| 2025-07-11 | 2.08x |
| 2025-07-10 | 2.11x |
| 2025-07-09 | 2.09x |
| 2025-07-08 | 2.08x |
| 2025-07-07 | 2.07x |
| 2025-07-03 | 2.10x |
| 2025-07-02 | 2.10x |
| 2025-07-01 | 2.10x |
| 2025-06-30 | 2.06x |
| 2025-06-27 | 2.06x |
| 2025-06-26 | 2.07x |
| 2025-06-25 | 2.03x |
| 2025-06-24 | 2.01x |
| 2025-06-23 | 1.99x |
| 2025-06-20 | 1.99x |
| 2025-06-18 | 2.01x |
| 2025-06-17 | 1.99x |
| 2025-06-16 | 2.03x |
Showing the most recent 260 of 844 data points. The chart above shows the full history.
Related Metrics
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini